Loading clinical trials...
Loading clinical trials...
A Phase 1, Placebo-Controlled, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-05180999 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
Yes
Pfizer Investigational Site
New Haven, Connecticut, United States
Start Date
August 1, 2011
Primary Completion Date
December 1, 2011
Completion Date
December 1, 2011
Last Updated
April 12, 2012
29
ACTUAL participants
PF-05180999
DRUG
Placebo
DRUG
Lead Sponsor
Pfizer
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions